Ameriprise Financial Inc. trimmed its holdings in Curis, Inc. (NASDAQ:CRIS) by 33.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 316,884 shares of the biotechnology company’s stock after selling 159,889 shares during the quarter. Ameriprise Financial Inc. owned about 0.22% of Curis worth $599,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares in the last quarter. Prudential Financial Inc. acquired a new position in Curis in the first quarter valued at approximately $105,000. Alliancebernstein L.P. boosted its holdings in Curis by 338.7% in the second quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 64,700 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Curis in the second quarter valued at approximately $163,000. Finally, BB&T Securities LLC acquired a new position in Curis in the second quarter valued at approximately $179,000. 44.67% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Curis, Inc. (CRIS) Shares Sold by Ameriprise Financial Inc.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/12/curis-inc-cris-shares-sold-by-ameriprise-financial-inc.html.

A number of equities analysts recently issued reports on CRIS shares. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Guggenheim started coverage on Curis in a report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine raised Curis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $6.50.

Shares of Curis, Inc. (NASDAQ CRIS) opened at $1.23 on Friday. Curis, Inc. has a fifty-two week low of $1.20 and a fifty-two week high of $3.72. The company has a debt-to-equity ratio of 1.24, a quick ratio of 3.72 and a current ratio of 5.15.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). The firm had revenue of $2.44 million during the quarter, compared to analyst estimates of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. Curis’s revenue was up 38.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.21) earnings per share. analysts anticipate that Curis, Inc. will post -0.41 EPS for the current fiscal year.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.